

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM340633

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>SEQUENCE:</b>	2		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
CITIBANK, N.A.		05/07/2015	National Association: UNITED STATES
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	HORIZON PHARMA, INC.		
<b>Street Address:</b>	520 Lake Cook Road, Suite 520		
<b>City:</b>	Deerfield		
<b>State/Country:</b>	ILLINOIS		
<b>Postal Code:</b>	60015		
<b>Entity Type:</b>	CORPORATION: DELAWARE		
<b>PROPERTY NUMBERS Total: 4</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4162441	RAYOS	
<b>Registration Number:</b>	4172965		
<b>Registration Number:</b>	4115724	RAYOS	
<b>Registration Number:</b>	3967638	HORIZON PHARMA	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	7147558290		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	714-540-1235		
<b>Email:</b>	ipdocket@lw.com		
<b>Correspondent Name:</b>	Latham & Watkins LLP		
<b>Address Line 1:</b>	650 Town Center Drive, Suite 2000		
<b>Address Line 4:</b>	Costa Mesa, CALIFORNIA 92626		
<b>ATTORNEY DOCKET NUMBER:</b>	049133-0129		
<b>NAME OF SUBMITTER:</b>	Anna T Kwan		
<b>SIGNATURE:</b>	/atk/		
<b>DATE SIGNED:</b>	05/07/2015		

OP \$115.00 4162441

**Total Attachments: 3**

source=Release Citi - Release of Trademark Security Execution Version#page1.tif

source=Release Citi - Release of Trademark Security Execution Version#page2.tif

source=Release Citi - Release of Trademark Security Execution Version#page3.tif

RELEASE OF SECURITY INTEREST IN TRADEMARKS

This RELEASE OF SECURITY INTEREST IN TRADEMARKS (this "Release"), dated as of May 7, 2015 by CITIBANK, N.A., as Administrative Agent and Collateral Agent for the Secured Parties (as defined in the Collateral Agreement referred to below, the "Agent"), in favor of HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. and VIDARA THERAPEUTICS INC. (now known as HZNP USA INC.) (collectively, the "Grantors"). All capitalized terms used but not otherwise defined herein have the meanings given to them in the Collateral Agreement (as defined below).

WHEREAS, the Grantors entered into that certain Credit Agreement dated as of June 17, 2014, and supplemented as of September 19, 2014 (as the same may be amended, restated, extended, supplemented or otherwise modified from time to time, the "Credit Agreement"),

WHEREAS, pursuant to the Credit Agreement, the Grantors executed and delivered that certain Trademark Security Agreement dated as of September 19, 2014 (the "Trademark Security Agreement") for recordation with the United States Patent and Trademark Office;

WHEREAS, the Trademark Security Agreement granted by Horizon Pharma, Inc. was recorded with the United States Patent and Trademark Office on November 11, 2014 at Reel 5399, Frame 0557, with a corrective filing on December 8, 2014 at Reel 5415, Frame 0763;

WHEREAS, the Trademark Security Agreement granted by Horizon Pharma USA, Inc. was recorded with the United States Patent and Trademark Office on November 11, 2014 at Reel 5399, Frame 0531, with a corrective filing on December 8, 2014 at Reel 5415, Frame 0797;

WHEREAS, the Trademark Security Agreement granted by Vidara Therapeutics Inc. (now known as HZNP USA Inc.) was recorded with the United States Patent and Trademark Office on November 11, 2014 at Reel 5399, Frame 0510, with a corrective filing on December 8, 2014 at Reel 5415, Frame 0840;

WHEREAS, pursuant to the Notice of Grant of Security Interest, the Grantor granted to the Agent for the ratable benefit of the Secured Parties a continuing security interest in and continuing lien upon the Trademarks, including the United States Trademarks identified on Schedule 1 hereto (the "Trademark Collateral"); and


WHEREAS, the Agent desires to terminate and release the security interest in and lien upon the Trademark Collateral.

NOW, THEREFORE, for and in consideration of the foregoing, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby terminates, discharges and releases the security interest and lien on the Trademark Collateral, without representation, warranty, or recourse.

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, the Agent has caused this Release to be executed by its duly authorized signatory effective as of the date first above written.

CITIBANK, N.A., as Agent





By:   
Name: Stuart Dickson  
Title: Vice President

Release of Trademark Security

**TRADEMARK**  
**REEL: 005512 FRAME: 0449**

**SCHEDULE 1**

**TRADEMARKS**

<b>Trademark</b>	<b>App. No.</b>	<b>Reg. No.</b>	<b>Current Owner</b>
DUEXA	77531169	3750439	Horizon Pharma USA, Inc.
DUEXIS	77531168	3764313	Horizon Pharma USA, Inc.
H 	77548415	3750459	Horizon Pharma USA, Inc.
RAYOS 	85394591	4162441	Horizon Pharma, Inc.
Design Only 	85394354	4172965	Horizon Pharma, Inc.
RAYOS	85096821	4115724	Horizon Pharma, Inc.
HORIZON PHARMA	85007094	3967638	Horizon Pharma, Inc.
COM3PASS COMPREHENSIVE PERSONALIZED PATIENT PRESCRIPTION ADVOCACY & SUPPORT SERVICES 	86023656	4627200	HZNP USA Inc.